Management to host conference call and webcast on May 13th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , May 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today

Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 9:00am PT SAN DIEGO , April 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel

SAN DIEGO , April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreement for the

Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. ATYR2810 used in combination with chemotherapy or bevacizumab increased anti-tumor effects in triple-negative breast cancer model.

Ms. Wilson to advise company on patient strategies related to clinical program for ATYR1923 in pulmonary sarcoidosis SAN DIEGO , April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on

Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter. Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favorable safety profile and signals of activity based on

Management to host conference call and webcast on March 23rd at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , March 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,

  Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings from animal models. SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

SAN DIEGO , March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American

Dr. Varner to advise company on mechanistic understanding of Neuropilin-2 (NRP2) and the development of novel anti-NRP2 antibody therapeutics for cancer SAN DIEGO , March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and